본문으로 건너뛰기
← 뒤로

Sevabertinib in Advanced -Mutant Non-Small-Cell Lung Cancer.

1/5 보강
The New England journal of medicine 📖 저널 OA 2.4% 2022: 0/6 OA 2023: 1/3 OA 2024: 0/5 OA 2025: 1/25 OA 2026: 1/41 OA 2022~2026 2025 Vol.393(18) p. 1819-1832
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
209 patients received sevabertinib (as of June 27, 2025, the data-cutoff date); the median duration of follow-up was 13.
I · Intervention 중재 / 시술
HER2-directed antibody-drug conjugates; and cohort F, patients who had not previously received treatment
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Diarrhea was the most common adverse event. (Funded by Bayer; SOHO-01 ClinicalTrials.gov number, NCT05099172.).

Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, Fang Y, Lu S, Dong X, Wu L, Shinno Y, Daniele G, Yang TY, Kim HR, Ruiter G, Zhao J, Novello S, Miao L, Jänne PA, Goto K, Rüttinger D, Descamps T, Brase JC, Bao W, Li R, Brega N, Grassi P, Girard N, Tan DS

📝 환자 설명용 한 줄

[BACKGROUND] gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC).

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 95% CI 6.3 to 13.5
  • 추적기간 13.8 months

이 논문을 인용하기

↓ .bib ↓ .ris
APA Le X, Kim TM, et al. (2025). Sevabertinib in Advanced -Mutant Non-Small-Cell Lung Cancer.. The New England journal of medicine, 393(18), 1819-1832. https://doi.org/10.1056/NEJMoa2511065
MLA Le X, et al.. "Sevabertinib in Advanced -Mutant Non-Small-Cell Lung Cancer.." The New England journal of medicine, vol. 393, no. 18, 2025, pp. 1819-1832.
PMID 41104928 ↗

Abstract

[BACKGROUND] gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models.

[METHODS] We conducted an open-label, multicenter, multicohort, phase 1-2 study to evaluate sevabertinib at a twice-daily dose of 20 mg in patients with locally advanced or metastatic -mutant NSCLC. Three cohorts were defined according to previous therapy: cohort D comprised previously treated patients who had not received HER2-targeted therapy; cohort E, patients who had previously received HER2-directed antibody-drug conjugates; and cohort F, patients who had not previously received treatment. The primary end point was an objective response, as assessed by blinded independent central review. Secondary end points were duration of response and progression-free survival.

[RESULTS] A total of 209 patients received sevabertinib (as of June 27, 2025, the data-cutoff date); the median duration of follow-up was 13.8 months in cohort D, 11.7 months in cohort E, and 9.9 months in cohort F. Among 81 patients in cohort D, an objective response was observed in 64% (95% confidence interval [CI], 53 to 75); the median duration of response was 9.2 months (95% CI, 6.3 to 13.5), and the median progression-free survival was 8.3 months (95% CI, 6.9 to 12.3). Among 55 patients in cohort E, an objective response was observed in 38% (95% CI, 25 to 52); the median duration of response was 8.5 months, and the median progression-free survival was 5.5 months. Among 73 patients in cohort F, an objective response was observed in 71% (95% CI, 59 to 81), and the median duration of response was 11.0 months; data on progression-free survival were immature. Grade 3 or higher drug-related adverse events occurred in 31% of the patients. The most common adverse event was diarrhea (in 84 to 91%), with diarrhea of grade 3 or higher occurring in 5 to 23%. Treatment was discontinued by 3% of the patients owing to drug-related adverse events.

[CONCLUSIONS] Sevabertinib showed antitumor activity in patients with locally advanced or metastatic -mutant NSCLC. Diarrhea was the most common adverse event. (Funded by Bayer; SOHO-01 ClinicalTrials.gov number, NCT05099172.).

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (4)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반